NuPathe Inc.

NuPathe — Investor Presentation (October 2011)

21 slides from NuPathe's investor presentation, Oct 3, 2011

  1. Slide 1: Corporate Presentation October 3, 2011

    Corporate Presentation October 3, 2011

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All remarks and information that are not historical facts are hereby identified as forward-looking statements for this purpose and include,

  3. Slide 3: Highlights

    3 Highlights . Emerging biopharmaceutical company focused on innovative neuroscience solutions • Marrying patient needs with commercial opportunity . Migraine patch • Efficacy established in robust phase III program • Large underserved market . Migraine-related nausea (MRN) is key commercial driver

  4. Slide 4: Triptans Dominate the Migraine Market

    Triptans Dominate the Migraine Market . Triptan market • 129 MM units in the U.S. • 97% of migraine sales . Preferred class of migraine treatment • 3-4 triptans tried before moving to different class Total U.S. Migraine Rxs = 13 million Data: MAT June 2011. Triptans include Treximet. Analgesic combo

  5. Slide 5: Harnessing the Power of Triptans

    5 Harnessing the Power of Triptans Patch applied during migraine attack . Powered by SmartReliefTM . Controlled delivery for four hours . Applied to upper arm or thigh . Single use, disposable

  6. Slide 6: Why a Patch for Migraine?

    6 Why a Patch for Migraine? * Overlap amongst patient types 1 2 3 Migraine-Related Nausea & Vomiting “MRN” Nausea 90% of treated patients 12.5 million patient opportunity* Vomiting 59% of treated patients 8 million patient opportunity* Gastroparesis Unreliable absorption Inconsistent Efficacy >40% o

  7. Slide 7: Patient Type and Patient Opportunity

    Patient Type % of Treated Patients Patient Opportunity* Migraine-Related Nausea (MRN) 90% ~12.5 M Migraine-Related Vomiting 59% ~8 M Progress to a 2nd Triptan 80% ~11 M Progress to a 3rd Triptan 50% ~6.5 M Experience Inconsistent Efficacy >40% ~6 M Adverse Events Impacts Treatment 67% ~9 M Taste Abn

  8. Slide 8: MRN is the Key Commercial Driver

    MRN is the Key Commercial Driver . 50% of patients experience frequent MRN (> 50% of migraines)1 . Those with frequent MRN are significantly less satisfied with their migraine medications1 • Greater dissatisfaction with medication effectiveness; report more side effects • More medication-related int

  9. Slide 9: The Ideal PK Profile

    9 Therapeutic Level The Ideal PK Profile Control provided by SmartRelief allows our migraine patch to deliver therapeutic levels with minimal Cmax related AEs 100mg oral 6mg SQ 20mg nasal Migraine patch Plasma levels (ng/ml) hours post closing

  10. Slide 10: Pivotal Phase III Data Confirms Value

    10 Pivotal Phase III Data Confirms Value v Not statistically significant . Rapid & sustained headache pain relief and elimination of nausea • 39% more NP101 patients had pain relief than placebo at 30 minutesv • Sustained pain relief from 2 to 24 hours (P=0.0015) • Significant elimination of nausea

  11. Slide 11: Pivotal Phase III Data Adverse Event Profile

    11 Pivotal Phase III Data Adverse Event Profile Application site events were typical of patches . Majority were mild in intensity and transient Minimal incidence of adverse events know as triptan sensations . Compared to product labeling for oral (12 – 14%) and injection (47%) Patch Placebo Applicat

  12. Slide 12: Comprehensive Safety Profile

    Comprehensive Safety Profile 12 . Extensive Phase III program including more than 800 patients and 10,000 patch applications . No drug-related serious adverse events . Two 12-month, repeat use, open label trials . Very low incidence of triptan sensations (<1%) . No increased skin irritation with rep

  13. Slide 13: Regulatory Status

    Regulatory Status . NDA submitted October 2010 . Complete response letter from FDA received August 29th • Efficacy in overall migraine population acknowledged • FDA complete response focused on chemistry, manufacturing and safety questions . End-of-review meeting scheduled for November 9th • Aggress

  14. Slide 14: Specialist Focus with PCP Opportunity

    14 Specialist Focus with PCP Opportunity . NuPathe (~100 Sales Reps) • Neurologists, headache specialists . Partnership / Expansion • Primary care Physicians Migraine Units Deciles Physicians Migraine Units Launch 100 Sales Reps 10 - 8 10,500 53 million Expansion Opportunity 7 - 5 31,000 53 million

  15. Slide 15: Broad Formulary Coverage Expected for Patch

    15 Broad Formulary Coverage Expected for Patch . Payers see value in the patch • GI issues acknowledged • Poorly controlled patients are costly • Patch addresses need for acceptable non-oral . Payers Indicate broad formulary access • Mix of tier 2 & 3 . Non-orals priced up to $87 per unit (WAC) • Br

  16. Slide 16: NP101 Franchise Opportunity

    NP101 Franchise Opportunity Program Research Phase I Phase II Phase III NDA Sumatriptan Iontophoretic Transdermal System NP101 - Acute Treatment of Migraine (US) NP101 – Acute Treatment of Migraine (Ex-US) NP101 – Pediatric Migraine (sNDA) NP101 – Cluster Headache (sNDA) NP101 – Predictable Migraine

  17. Slide 17: Building Our Patch Franchise Beyond Migraine

    Building Our Patch Franchise Beyond Migraine 17 Proteins/ Peptides Nucleic Acids Small Molecules Global transdermal delivery market to grow from $21.5 billion in 2010 to $31.5 billion by 2015* Source: PharmaLive Special Reports: Transdermal Medicine Review and Outlook, September 2011

  18. Slide 18: Biodegradable Implant Portfolio

    18 Biodegradable Implant Portfolio . NP201: Long–acting delivery (LAD) of ropinirole to treat the signs and symptoms of Parkinson’s disease • Designed to address tolerability and need for consistent long-term efficacy • Evidence suggests continuous dopaminergic stimulation delays disease progression

  19. Slide 19: Pipeline Addresses Large Unmet Needs

    19 Pipeline Addresses Large Unmet Needs Program Pre-Clinical Phase I Phase III Ropinirole Biodegradable Implant NP201 – Treatment of Parkinson’s Disease NP201 – Delayed Progression of Parkinson’s Disease (sNDA) NP201 – Treatment of Restless Leg Syndrome Atypical Antipsychotic Biodegradable Implant N

  20. Slide 20: Highlights

    20 Highlights . Emerging biopharmaceutical company focused on innovative neuroscience solutions • Marrying patient needs with commercial opportunity . Migraine patch • Efficacy established in robust phase III program • Large underserved market . Migraine-related nausea (MRN) is key commercial driver

  21. Slide 21: NuPathe Innovating Neuroscience

    000, NuPathe Innovating Neuroscience

NuPathe — Investor Presentation (October 2011) on 6ix